Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 May;51(5):681–689. doi: 10.1038/bjc.1985.103

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.

A Gabizon, D Goren, Z Fuks, A Meshorer, Y Barenholz
PMCID: PMC1977062  PMID: 3994911

Abstract

We have examined the anti-tumour activity of liposome-entrapped Adriamycin in a murine metastatic tumour model produced by i.v. inoculation of J-6456 lymphoma cells and affecting predominantly the liver. Sonicated liposomes containing phosphatidylcholine, a negatively-charged phospholipid and cholesterol were used in these experiments. Liposome-entrapped Adriamycin was more effective than free Adriamycin at equivalent doses of the drug. The superior therapeutic effect of the liposome-associated drug was manifest, either with a single i.v. treatment using a dose bordering the toxicity threshold of free Adriamycin or with a multi-injection schedule using smaller doses. Based on the growth kinetics data of the J-6456 lymphoma, our results indicate that tumour cell killing was enhanced by a factor of approximately 100 using the liposome associated form of Adriamycin. Histopathologic studies in mice bearing well-established metastases of the J-6456 lymphoma in liver and spleen indicated that the extent and duration of pathologic remission were significantly improved in mice receiving the liposome-entrapped drug as compared to mice receiving free drug. No significant differences in the anti-tumour effect of liposome entrapped Adriamycin were observed replacing phosphatidylserine by phosphatidylglycerol and reducing the cholesterol:phospholipid molar ratio from 100% to 25%. In contrast to the metastatic tumour model, liposome-entrapped Adriamycin was significantly less effective than free Adriamycin on the local i.m. growth of the J-6456 tumour. Altogether the survival and histopathological data presented suggest that, with regard to a group of neoplastic conditions with a predominant pattern of liver dissemination, a substantial increase in the therapeutic index of Adriamycin can be achieved in a selective manner with the use of liposomes.

Full text

PDF
681

Images in this article

686Figure 5
on p.686
686Figure 6
on p.686
687Figure 7
on p.687

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Comfurius P., Zwaal R. F. The enzymatic synthesis of phosphatidylserine and purification by CM-cellulose column chromatography. Biochim Biophys Acta. 1977 Jul 20;488(1):36–42. doi: 10.1016/0005-2760(77)90120-5. [DOI] [PubMed] [Google Scholar]
  2. Fidler I. J., Hart I. R. Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res. 1981 Aug;41(8):3266–3267. [PubMed] [Google Scholar]
  3. Forssen E. A., Tökes Z. A. In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Commun. 1979 Dec 28;91(4):1295–1301. doi: 10.1016/0006-291x(79)91207-5. [DOI] [PubMed] [Google Scholar]
  4. Forssen E. A., Tökès Z. A. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1873–1877. doi: 10.1073/pnas.78.3.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Forssen E. A., Tökés Z. A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 1983 Feb;43(2):546–550. [PubMed] [Google Scholar]
  6. Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 1982 Nov;42(11):4734–4739. [PubMed] [Google Scholar]
  7. Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A., Meshorer A. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res. 1983 Oct;43(10):4730–4735. [PubMed] [Google Scholar]
  8. Gabizon A., Trainin N. Enhancement of growth of a radiation-induced lymphoma by T cells from normal mice. Br J Cancer. 1980 Oct;42(4):551–558. doi: 10.1038/bjc.1980.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J. M. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta. 1980 Mar 27;597(1):1–14. doi: 10.1016/0005-2736(80)90145-5. [DOI] [PubMed] [Google Scholar]
  10. Herman E. H., Rahman A., Ferrans V. J., Vick J. A., Schein P. S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983 Nov;43(11):5427–5432. [PubMed] [Google Scholar]
  11. Kaye S. B., Boden J. A., Ryman B. E. The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours. Eur J Cancer. 1981 Mar;17(3):279–289. doi: 10.1016/0014-2964(81)90119-5. [DOI] [PubMed] [Google Scholar]
  12. Levi-Schaffer F., Bernstein A., Meshorer A., Arnon R. Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat Rep. 1982 Jan;66(1):107–114. [PubMed] [Google Scholar]
  13. Machy P., Leserman L. D. Small liposomes are better than large liposomes for specific drug delivery in vitro. Biochim Biophys Acta. 1983 May 5;730(2):313–320. doi: 10.1016/0005-2736(83)90348-6. [DOI] [PubMed] [Google Scholar]
  14. Martin F., Caignard A., Olsson O., Jeannin J. F., Leclerc A. Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. Cancer Res. 1982 Sep;42(9):3851–3857. [PubMed] [Google Scholar]
  15. Matthay K. K., Heath T. D., Papahadjopoulos D. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles. Cancer Res. 1984 May;44(5):1880–1886. [PubMed] [Google Scholar]
  16. Mayhew E., Rustum Y., Vail W. J. Inhibition of liver metastases of M 5076 tumor by liposome-entrapped adriamycin. Cancer Drug Deliv. 1983;1(1):43–58. doi: 10.1089/cdd.1983.1.43. [DOI] [PubMed] [Google Scholar]
  17. Olson F., Mayhew E., Maslow D., Rustum Y., Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol. 1982 Feb;18(2):167–176. doi: 10.1016/0277-5379(82)90060-8. [DOI] [PubMed] [Google Scholar]
  18. Pattengale P. K., Frith C. H. Immunomorphologic classification of spontaneous lymphoid cell neoplasms occurring in female BALB/c mice. J Natl Cancer Inst. 1983 Jan;70(1):169–179. [PubMed] [Google Scholar]
  19. Poste G., Bucana C., Raz A., Bugelski P., Kirsh R., Fidler I. J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982 Apr;42(4):1412–1422. [PubMed] [Google Scholar]
  20. Pownall H. J., Massey J. B., Kusserow S. K., Gotto A. M., Jr Kinetics of lipid--protein interactions: effect of cholesterol on the association of human plasma high-density apolipoprotein A-I with L-alpha-dimyristoylphosphatidylcholine. Biochemistry. 1979 Feb 20;18(4):574–579. doi: 10.1021/bi00571a004. [DOI] [PubMed] [Google Scholar]
  21. Rahman A., Kessler A., More N., Sikic B., Rowden G., Woolley P., Schein P. S. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980 May;40(5):1532–1537. [PubMed] [Google Scholar]
  22. Rahman A., More N., Schein P. S. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res. 1982 May;42(5):1817–1825. [PubMed] [Google Scholar]
  23. Richardson V. J., Ryman B. E. Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo. Br J Cancer. 1982 Apr;45(4):552–558. doi: 10.1038/bjc.1982.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Roseman M., Litman B. J., Thompson T. E. Transbilayer exchange of phosphatidylethanolamine for phosphatidylcholine and N-acetimidoylphosphatidylethanolamine in single-walled bilayer vesicles. Biochemistry. 1975 Nov 4;14(22):4826–4830. doi: 10.1021/bi00693a008. [DOI] [PubMed] [Google Scholar]
  25. Segal A. W., Wills E. J., Richmond J. E., Slavin G., Black C. D., Gregoriadis G. Morphological observations on the cellular and subcellular destination of intravenously administered liposomes. Br J Exp Pathol. 1974 Aug;55(4):320–327. [PMC free article] [PubMed] [Google Scholar]
  26. Shubik P. Vascularization of tumors: a review. J Cancer Res Clin Oncol. 1982;103(3):211–226. doi: 10.1007/BF00409698. [DOI] [PubMed] [Google Scholar]
  27. Snyder B., Freire E. Compositional domain structure in phosphatidylcholine--cholesterol and sphingomyelin--cholesterol bilayers. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4055–4059. doi: 10.1073/pnas.77.7.4055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Straubinger R. M., Hong K., Friend D. S., Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. Cell. 1983 Apr;32(4):1069–1079. doi: 10.1016/0092-8674(83)90291-x. [DOI] [PubMed] [Google Scholar]
  29. Szoka F., Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9:467–508. doi: 10.1146/annurev.bb.09.060180.002343. [DOI] [PubMed] [Google Scholar]
  30. Talmadge J. E., Key M., Fidler I. J. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol. 1981 Jun;126(6):2245–2248. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES